Obesity and COVID-19
https://doi.org/10.18705/1607-419X-2020-26-4-440-446
Abstract
The infectious disease COVID-19, induced by virus SARS-CoV-2, is associated with high morbidity and mortality. Considering the COVID-19 pandemic since the beginning of 2020, the recognition of its risk and prognostic factors with the identification of the most vulnerable groups of population is highly relevant. The relationship between the severity of COVID-19 and diabetes mellitus, hypertension, and cancer has been confirmed. The management of patients with concomitant somatic pathology during the development of COVID-19 is widely discussed. Obesity is one of the most common noninfectious diseases in modern society, which can directly and indirectly aggravate the course and increase mortality from COVID-19. Obesity is also considered a risk factor for COVID-19 morbidity and mortality. This review presents data on the effects of obesity on the coronavirus infection and the management of obese patients during the COVID-19 pandemic.
About the Authors
E. N. KravchukRussian Federation
Ekaterina N. Kravchuk - MD, PhD, Senior Researcher, Research Laboratory of the Surgery Treatment of Metabolic Disorders, Institute of Endocrinology.
St Petersburg
A. E. Neimark
Russian Federation
Aleksandr E. Neimark - MD, PhD, Head, Research Laboratory of the Surgery Treatment of Metabolic Disorders, Institute of Endocrinology.
St Petersburg
A. Yu. Babenko
Russian Federation
Alina Yu. Babenko - MD, PhD, DSc, Head, Research Laboratory of Diabetology, Institute of Endocrinology.
St Petersburg
E. N. Grineva
Russian Federation
Elena N. Grineva - MD, PhD, DSc, Director, Institute of Endocrinology.
St PetersburgReferences
1. De Lorenzo A, Gratteri S, Gualtieri P, Cammarano A, Bertucci P, Di Renzo L. Why primary obesity is a disease? J Transl Med. 2019;17(1):169. doi:10.1186/s12967-019-1919-y
2. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. J Am Med Assoc. 2020. [Ahead of print, published online 24 February 2020]. doi:10.1001/jama.2020.2648.
3. Ryan DH, Ravussin E, Heymsfield S. COVID 19 and the patient with obesity—the editors speak out. Obesity (Silver Spring). 2020;28(5):847. doi:10.1002/oby.22808
4. Dietz W, Santos-Burgoa C. Obesity and its implications for COVID-19 mortality. Obesity (Silver Spring). 2020;28(6):1005. [Ahead of print, published online 18 April 2020]. doi:10.1002/oby.22818.
5. Louie JK, Acosta M, Winter K, Jean C, Gavali S, Schechter R et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A (H1N 1) infection in California. J Am MedAssoc. 2009;302(17):1896-1902. doi:10.1001/jama.2009.1583
6. Murphy R, Fragaszy EB, Hayward AC, Warren-Gash C. Investigating obesity as a risk factor for influenza-like illness during the 2009 H1N 1 influenza pandemic using the Health Survey for England. Influenza Other Respir Viruses. 2017;11(1): 66—73. doi:10.11n/irv.12420
7. Thompson DL, Jungk J, Hancock E, Smelser C, Landen M, Nichols M et al. Risk factors for 2009 pandemic influenza A (H1N 1)-related hospitalization and death among racial/ethnic groups in New Mexico. Am J Public Health. 2011;101(9):1776—84. doi:10.2105/AJPH.2011.300223
8. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring). 2020. [Ahead of print, published online 10 June 2020]. doi:10.1002/oby.22831
9. Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clin Infect Dis. 2020. [Ahead of print, published online 9 April 2020].pii:ciaa415. doi:10.1093/cid/ciaa415
10. Obesity prevention. [Electronic resource]. URL: https://www.health.ny.gov/prevention/obesity/
11. Hales CM, Fryar CD, Carroll MD, Freedman DS, Ogden CL. Trends in obesity and severe obesity prevalence in US youth and adults by sex and age. 2007-2008 to 2015-2016. J Am MedAssoc. 2018;319(16):1723-1725. doi:10.1001/jama.2018.3060
12. Peng YD, Meng K, Guan HQ, Leng L, Zhu RR, Wang BY et al. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48: E 004. [Ahead of print, published online 9 April 2020]. doi:10.3760/cma.j.cn112148-20200220-00105
13. CNARC report on COVID-19 in critical care 08 May 2020. Available from: https://www.icnarc.org/Our-Audit/Audits/Cmp/Reports
14. MalavazosAE, Corsi Romanelli MM, Bandera F, Iacobellis G. Targeting the adipose tissue in COVID-19. Obesity (Silver Spring). 2020;28(7):1178-1179. doi:10.1002/oby.22844.
15. Boykov VA, Kobyakova OS, Deyev IA, Kulikov YS, Starovoytova YA. State of respiratory function in patients with obesity. Bulletin of Siberian Medicine. 2013;12(1):86-92. doi:10.20538/1682-0363-2013-1-86-92. In Russian.
16. Attaur-Rasool S, Khan Shirwany TA. Body mass index and dynamic lung volumes in office workers. J Coll Physicians Surg Pak. 2012;22(3):163-167. doi:02.2012/JCPSP.163167
17. Bochkarev MV, Korostovtseva LS, Filchenko IA, Rotar OP, Sviryaev YV, Zhernakova YV et al. Complaints on sleep breathing disorder and cardiovascular risk factors in Russian regions: data from ESSE-RF study. Russ J Cardiol. 2018;(6):152-158. doi:10.15829/1560-4071-2018-6-152-158. In Russian.
18. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85-97. doi:10.1038/nri2921
19. Honce R, Schultz-Cherry S. Impact of obesity on infuenza, a virus pathogenesis, immune response, and evolution. Front Immunol. 2019;10:1071. doi:10.3389/fimmu.2019.01071
20. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020. [Ahead of print, published online 12 March 2020]. pii: ciaa248. doi:10.1093/cid/ciaa248
21. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-147. doi:10.1016/j.thromres.2020.04.013.
22. Movahed MR, Khoubyari R, Hashemzadeh M, Hashemzadeh M. Obesity is strongly and independently associated with a higher prevalence of pulmonary embolism. Respir Investig. 2019;57(4):376-379. doi:10.1097/MBC.0b013e3283403537
23. De Pergola G, Pannacciulli N. Coagulation and fibrinolysis abnormalities in obesity. J Endocrinol Invest. 2002;25(10):899-904. doi:10.1007/BF03344054
24. Siklar Z, Ofal G, Berberoglu M, Hacihamdioglu B, Savas Erdeve S, Egin Y et al. Evaluation of hypercoagulability in obese children with thrombin generation test and microparticle release: effect of metabolic parameters. Clin Appl Thromb Hemost. 2011;17(6):585-589. doi:10.1177/1076029611404216
25. Santilli F, Vazzana N, Liani R, Guagnano MT, Davi G. Platelet activation in obesity and metabolic syndrome. Obes Rev. 2012;13(1):27-42. doi:10.1111/j.1467-789X.2011.00930.x
26. Borch KH, Nyegaard C, Hansen JB, Mathiesen EB, Nj0lstad I, Wilsgaard T et al. Joint effects of obesity and body height on the risk of venous thromboembolism: the Troms0 Study. Arterioscler Thromb Vasc Biol. 2011;31(6):1439-1444. doi:10.1161/ATVBAHA.110.218925
27. Freeman AL, Pendleton RC, Rondina MT. Prevention of venous thromboembolism in obesity. Expert Rev Cardiovasc Ther. 2010;8(12):1711-1721. doi:10.1586/erc.10.160
28. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W et al. Coagulopathy and antiphospholipid antibodies in patients with COVID-19. N Engl J Med. 2020;382(17):e38. doi:10.1056/NEJMc2007575
29. Griffin DO, Jensen A, Khan M, Chin J, Chin K, Saad J et al. Pulmonary embolism and increased levels of d-Dimer in patients with coronavirus disease. Emerg Infect Dis. 2020;26(8). [Ahead of print, published online 29 April 2020]. doi:10.3201/eid2608.201477
30. Tseng YH, Yang RC, Lu TS. Two hits to the reninangiotensin system may play a key role in severe COVID-19. Kaohsiung J Med Sci. 2020;36(6):389-392. doi: 10.1002/kjm2.12237
31. Leisman DE, Deutschman CS, Legrand M. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. Intensive Care Med. 2020;46(6): 1105-1108. doi:10.1007/s00134-020-06059-6.
32. Maier HE, Lopez R, Sanchez N, Ng S, Gresh L, Ojeda S et al. Obesity increased the duration of influenza A virus shedding in adults. J Infect Dis. 2018;218(9):1372-1382. doi:10.1093/infdis/jiy370
33. Yan J, Grantham M, Pantelic J, Bueno de Mesquita PJ, Albert B, Liu F et al. Infectious virus in exhaled breath of syptomatic seasonal infuenza cases from a college community. PNAS. 2018;115(5):1081—1086. doi:10.1073/pnas.1716561115
34. Jantaratnotai N, Mosikanon K, Lee Y, McIntyre RS. The interface of depression and obesity. Obes Res Clin Pract. 2017;11(1):1—10. doi:10.1016/j.orcp.2016.07.003
35. Yang W, Wang C, Shikora S, Kow L. Recommendations for metabolic and bariatric surgery during the COVID-19 pandemic from IFSO. Obes Surg. 2020;30(6):2071-2073. doi:10.1007/s11695-020-04578-1
36. Fruhbeck G, Baker JL, Busetto L, Dicker D, Goossens GH, Halford JCG et al. European association for the study of obesity position statement on the global COVID-19 pandemic. Obes Facts. 2020;13(2):292-296. doi:10.1159/000508082
37. Pietrobelli A, Pecoraro L, Ferruzzi A, Heo M, Faith M, Zoller T et al. Effects of COVID-19 lockdown on lifestyle behaviors in children with obesity living in Verona, Italy: A Longitudinal Study. Obesity (Silver Spring). 2020. [Ahead of print, published online 30 April 2020]. doi:10.1002/oby.22861.
38. Codella R, Luzi L, Inverardi L, Ricordi C. The antiinfammatory efects of exercise in the syndromic thread of diabetes and autoimmunity. Eur Rev Med Pharmacol Sci. 2015;19(19):3709— 3722.
39. Senesi P, Montesano A, Luzi L, Codella R, Benedini S, Terruzzi I. Metformin treatment prevents sedentariness related damages in mice. J Diabetes Res. 2016;2006:8274689. doi: 10.1155/2016/8274689
40. Darwish I, Mubareka S, Liles WS. Immunomodulatory therapy for severe infuenza. Expert Rev Anti Infect Ther. 2011;9(7):807-822.
Review
For citations:
Kravchuk E.N., Neimark A.E., Babenko A.Yu., Grineva E.N. Obesity and COVID-19. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2020;26(4):440-446. (In Russ.) https://doi.org/10.18705/1607-419X-2020-26-4-440-446